mRNA is a rapidly evolving area of medicine with huge potential. United by a sense of shared purpose, we’re working with our biopharma clients, deploying creative thinking and high-level problem solving to accelerate the development and delivery of potentially transformative treatments.  The delivery of facilities that are designed for higher production volumes and make treatments accessible to more patients is a crucial step towards revolutionizing modern medicine.

As the commercialization of autologous cell-therapy products gathers pace, wider access is becoming a reality. To ensure more people around the world can access these innovative treatments, we are partnering with clients to overcome operational and regulatory challenges as they scale out production.

With an increasing number of cell and gene therapy products receiving regulatory approval, there is a burning need to deliver projects that support the growth of groundbreaking treatments. We’re working hand-in-hand with clients to provide a flexible approach to facility design that addresses complex challenges as manufacturers ramp up production capacity.

Contract development and manufacturing organizations (CDMOs) are supporting a seismic shift in Life Sciences, with their highly flexible large-scale facilities increasing production capacity on a massive scale, reducing risk for pharma companies, and guaranteeing hyper-speed project delivery. We’re helping CDMO clients reach these previously unattainable production targets with a flexible approach realized using integrated project delivery (IPD).

Flexibility played a central role in the response to COVID-19, with solutions providers and Life Sciences companies working together at lightning speed to retro-fit existing facilities for vaccines and treatments. This approach is helping to futureproof the sector, enabling companies to scale manufacturing in response to evolving patient needs, providing fast-tracked access to potentially transformative medicines treatments and therapies for patients globally and addressing patient demand for new treatments and therapies.